Piramal Pharma Crosses USD 1 Billion Revenue, Announces SBTi Approved Decarbonisation Plan

Piramal Pharma Ltd, a part of the Piramal Group, has reported a steady financial year 2024-25 with a revenue from operations of INR 21,580 Crore (USD 2.7 Billion), crossing the USD 1 Billion milestone. The company also announced its SBTi approved decarbonisation plan, aiming to reduce emissions by 42% by FY2030. The company operates in three core segments: CDMO, Complex Hospital Generics, and Consumer Healthcare in India, with a global network of 171 state-of-the-art facilities. Piramal Pharma Solutions, the CDMO business, supports innovation-driven pharma companies in delivering cutting-edge products. The company's CHG and PCH business offers a wide range of differentiated products across hospital generics and consumer/OTC healthcare and wellness segments in over 30 countries.